The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 study of berzosertib (M6620) in combination with carboplatin compared with docetaxel in combination with carboplatin in metastatic castration-resistant prostate cancer.
 
Atish Dipankar Choudhury
Employment - LeMaitre Vascular (I)
Honoraria - Astellas Pharma; Bayer; Janssen; Journal of Clinical Pathways/Oncology Learning Network; OncLive; OncLive; OncLive
Consulting or Advisory Role - Bayer; Clovis Oncology; Dendreon; MedaCorp
Research Funding - Bayer; Janssen (Inst)
Travel, Accommodations, Expenses - Genentech
 
Wanling Xie
No Relationships to Disclose
 
Edmund Folefac
No Relationships to Disclose
 
Daniel Lee
No Relationships to Disclose
 
Mamta Parikh
Consulting or Advisory Role - Exelixis; Janssen; Janssen; Seagen
 
David Johnson Einstein
Honoraria - OncLive
Research Funding - Bristol-Myers Squibb (Inst); Cardiff Oncology (Inst); Foundation Medicine (Inst); Puma Biotechnology (Inst)
 
Elizabeth R Kessler
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Medivation/Astellas; Pfizer (Inst)
 
Tina M. Mayer
Honoraria - EMD Serono; Exelixis
Consulting or Advisory Role - AstraZeneca; Beacon Bioscience/ICON Medical; Novartis
Research Funding - Merck (Inst); Pfizer/EMD Serono; Sotio (Inst)
 
Rana R. McKay
Consulting or Advisory Role - Astellas Medivation; AstraZeneca; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Dendreon; Exelixis; Janssen; Merck; Novartis; Pfizer; Sanofi; Tempus; Vividion Therapeutics
Research Funding - Bayer (Inst); Pfizer (Inst); Tempus (Inst)
 
Amanda Fredericks Pace
Employment - Dicerna (I)
Consulting or Advisory Role - Carevive; Seagen
 
Bose Kochupurakkal
Employment - Amgen (I)
Stock and Other Ownership Interests - Amgen (I)
Research Funding - Lilly
 
Kent William Mouw
Honoraria - OncLive/MJH Life Sciences; UpToDate
Research Funding - Pfizer
 
Eliezer Mendel Van Allen
Stock and Other Ownership Interests - ervaxx; Genome Medical; Manifold Bio; Microsoft; Monte Rosa Therapeutics; Syapse; Tango Therapeutics
Consulting or Advisory Role - ervaxx; Genome Medical; Illumina; InVitae; Janssen; Manifold Bio; Monte Rosa Therapeutics; Novartis; Roche; Syapse; Takeda; Tango Therapeutics; Third Rock Ventures
Speakers' Bureau - Illumina
Research Funding - Bristol-Myers Squibb; Novartis
Patents, Royalties, Other Intellectual Property - Patent on clinical interpretation algorithms using cancer molecular data (Inst); Patent on discovery of chromatin regulators as biomarkers of response to cancer immunotherapy (Inst); Patent on discovery of retained intron as source of cancer neoantigens (Inst)
Travel, Accommodations, Expenses - Roche/Genentech
 
Charles Kunos
No Relationships to Disclose
 
Alan D. D'Andrea
Stock and Other Ownership Interests - Cedilla Therapeutics; Cyteir; Ideaya, Inc.
Consulting or Advisory Role - AstraZeneca; Bayer; Cedilla Therapeutics; Celgene; cyteir; Epizyme; GlaxoSmithKline; Ideaya, Inc.; IMPAC Medical Systems; LEK; Merck Serono; Novartis Bioventures; Novo Ventures; Pfizer; Scholar Rock; Tango Therapeutics; Vida Ventures
Research Funding - Lilly; Merck Serono
Travel, Accommodations, Expenses - IDEAYA Biosciences
 
Mary-Ellen Taplin
Honoraria - Abbvie; Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca; Bayer; Celgene; Clovis Oncology; Constellation Pharmaceuticals; GlaxoSmithKline; Guidepoint Global; Incyte; Janssen-Ortho; Merck; Myovant Sciences; Pfizer; Pfizer; Progenics; Research to Practice; Roivant; UpToDate
Consulting or Advisory Role - Arcus Ventures (I); AstraZeneca; Bayer; Best Doctors, Inc; Clovis Oncology; Guidepoint Global; Incyte; Janssen-Ortho; Myovant Sciences; Pfizer; Research to Practice; UpToDate
Research Funding - Bayer (Inst); Janssen-Ortho (Inst); Medivation (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Clovis Oncology; Incyte; Janssen Oncology; Medivation; Pfizer; Tokai Pharmaceuticals
 
Geoffrey Shapiro
Consulting or Advisory Role - Almac Diagnostics; Angiex; Artios; Astex Pharmaceuticals; Atrin Pharmaceuticals; Bayer; Bicycle Therapeutics; Boehringer Ingelheim; Concarlo; Cybrexa Therapeutics; CytomX Therapeutics; Daiichi Sankyo; Fusion Pharmaceuticals; G1 Therapeutics; Ipsen; Lilly; Merck Serono; Pfizer; Roche; Seagen; Sierra Oncology; Syros Pharmaceuticals; Zentalis
Research Funding - Aileron Therapeutics (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CanBas (Inst); Cellceutix (Inst); Clovis Oncology (Inst); Covidien (Inst); Curis (Inst); Cyclacel (Inst); Esperas Pharma (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immune Design (Inst); Lilly (Inst); Merck (Inst); Merck Serono (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); PTC Therapeutics (Inst); Puma Biotechnology (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Sierra Oncology (Inst); Syros Pharmaceuticals (Inst); Tensha Therapeutics (Inst); Tesaro (Inst); Vertex (Inst)
Patents, Royalties, Other Intellectual Property - Patent #: 9872874 Title: Dosage regimen for sapacitabine and seliciclib Issue Date: 1/23/2018; Provisional Patent #:62/538,319 Title: Compositions and methods for predicting response and resistance to CDK4/6 inhibition Filed: 7/28/17
Travel, Accommodations, Expenses - Bayer; Bicycle Therapeutics; G1 Therapeutics; Lilly; Pfizer; Sierra Oncology